RKV.V Rakovina Therapeutics Inc
- Market cap
- CAD 4.88M
- P/E
- -
- P/B
- 20.43x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RKV.V undervalued?
Graham numberThe Graham number of Rakovina Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rakovina Therapeutics Inc fundamental analysis
No fundamental analysis for Rakovina Therapeutics Inc yet.
Rakovina Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which …
Full company profileRakovina Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rakovina Therapeutics Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | - | - | -2.47M | -2.82M | -2.48M | -3.79M | -8.29M | -6.11M |
| EBITDA | - | - | - | -2.06M | -2.26M | -1.93M | -3.27M | -7.74M | -5.75M |
| Net Income | - | - | - | -5.52M | -2.79M | -2.61M | -4.07M | -8.68M | -6.81M |
| EPS | - | - | - | -0.08 | -0.40 | -0.37 | -0.05 | -0.41 | -0.28 |
| Balance Sheet | |||||||||
| Total Assets | - | - | - | 8.66M | 6.12M | 5.15M | 6.24M | 4.24M | 3.54M |
| Total Liabilities | - | - | - | 114K | 107K | 1.49M | 1.94M | 4.10M | 5.72M |
| Shareholders' Equity | - | - | - | 8.54M | 6.01M | 3.66M | 4.30M | 140K | -2.18M |
| Cash & Short-term Investments | - | - | - | 2.81M | 897K | 436K | 1.31M | 299K | 200K |
| Cash Flow | |||||||||
| Operating Cash Flow | -126K | -59.7K | -52.00 | -2.31M | -1.92M | -1.86M | -3.86M | -5.82M | -3.61M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | -2.31M | -1.92M | -1.86M | -3.86M | -5.82M | -3.61M |
| Ratios | |||||||||
| ROE | - | - | - | -64.6% | -46.4% | -71.4% | -94.7% | -6,212.6% | - |
| ROA | - | - | - | -63.8% | -45.6% | -50.8% | -65.3% | -204.7% | -192.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Rakovina Therapeutics Inc dividends
Rakovina Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:10 on Jun 24, 2025.
Who owns Rakovina Therapeutics Inc
- Insiders 5.68%
- Institutions 0.00%
- Public & others 94.32%
- Shares outstanding 24.4M
- Free float 21.5M
Rakovina Therapeutics Inc company profile
- Company name
- Rakovina Therapeutics Inc
- Ticker
- RKV.V
- ISIN
- CA75103L1013
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
- Website
- rakovinatherapeutics.com
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR"mTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. Additionally, Rakovina Therapeutics Inc. has a strategic collaboration with Celvion Therapeutics to identify novel precision medicine strategies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Rakovina Therapeutics Inc management
4- Dr. David M. Kideckel M.B.A., Ph.D.CFO & Director · born 1981
- Mr. Kim OishiCEO & Director
- Dr. Mads Daugaard Ph.D.President & Chief Scientific Officer
- Dr. John Langlands Ph.D.Head of Development